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ABSTRACT 
The 19 members of the lipoglycoprotein family of WNTs interact with the highly 
conserved cysteine-rich domain (CRD) of ten members of the Frizzled (FZD1-10) family. The 
seven transmembrane-spanning surface receptors are listed as G protein-coupled receptors and 
are known to interact with heterotrimeric G proteins as well as the scaffolding protein 
disheveled. Upon ligand binding, activation of β-catenin-dependent and/or –independent 
pathways are induced. The WNT/Frizzled signaling pathway is highly conserved across species 
and plays an essential role in a plethora of physiological processes, such as embryonic stem 
cell differentiation, adult stem cell renewal, migration, proliferation and cell polarity. In 
humans, dysregulation of the pathway is related to developmental alterations, as well as 
numerous diseases, among which various types of cancers.  
The general aim of this thesis was to investigate the role of WNT/FZD signaling in 
physiological and pathophysiological processes of the central nervous system. Additionally, 
we attempted to dissect the molecular features of the WNT/FZD pathway regarding signaling 
specification, a contribution aimed at increasing the possibilities of future drug development.    
To date, WNT/FZD binding specificity, as well as the downstream signaling trigged by 
different ligand-receptor combinations, have not been systematically mapped. Furthermore, the 
involvement and role of heterotrimeric G proteins downstream of FZDs is unclear. In paper I, 
we demonstrated that WNT-5A is able to activate PTX-sensitive Gαi/o proteins in the microglia-
like cell line N13. Additionally, in paper II we concluded that WNT-3A, -4, and -5A have a 
putative functional selectivity for individual downstream signaling pathways depending on the 
FZD present.   
WNT-5A is known to be expressed in the central nervous system, where it plays a role 
in various neurological processes. However, it had not been fully delineated which cell type 
expresses and secretes WNT-5A in the brain. In paper IV, we identified a subpopulation of 
astrocytes that express high levels of WNT-5A in the brain of adult mice. These astrocytes are 
localized in the subventricular zone, the rostral migratory stream, and in the hippocampus. By 
studying a WNT-5A+/- mouse model, we show that some astrocytes release WNT-5A and fulfill 
a crucial role in guiding the migration of neuronal precursor cells from the subventricular zone 
to the olfactory bulb. In paper V, we investigated the pathological implications of WNT-5A 
signaling to the prognostics of human glioblastomas, and described a strong association 
between WNT-5A expression in in the tumor microenvironment and increased infiltration of 
microglia. 
Besides the role in neuronal precursor migration, WNT-5A induced a proinflammatory 
response in mouse microglia cells, shown by the expression of several proinflammatory 
markers (paper III). Additionally, WNT-5A induced proliferation, invasion and calcium 
signaling in microglia. By employing the Gαi/o inhibitor PTX, as well as the MEK1/2 inhibitor, 
a part of these events could be blocked, suggesting G protein-dependent mechanisms 
downstream of WNT-5A.  
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1 INTRODUCTION 
The 19 different isoforms of WNT proteins serve as ligands for the seven-transmembrane  
(7TM) Frizzled (FZD) receptor proteins (FZD1-10) upon which different downstream 
signaling pathways can be activated. This complex signaling network has been associated 
with a plethora of developmental processes such as stem cell proliferation, organogenesis 
as well as adult stem cell renewal. Dysregulation of the pathway is connected to a wide 
range of diseases among which different types of cancer and neurodegenerative diseases. 
Precisely because of their abundant role in both physiological and pathophysiological 
processes, this pathway is highly relevant and rewarding to study. To date around 30 
clinical studies are being conducted worldwide within the area of WNTs or FZDs, as 
registered on the clinical trial website of the National Institutes of Health (NIH, 2014). 
An example of a promising ongoing phase I clinical trial describes the use of a peptide 
named Foxy-5, which is able to mimic the effect of WNT-5A to impair migration of 
epithelial cancer cells. The researchers suggest therefore that this compound can 
potentially be used as an anti-metastatic cancer drug and thereby increase the survival 
rates of patients with solid malignant tumors.  
In this thesis I focus on the current understanding on WNT/FZD signaling in 
general, WNT and FZD signal specification and downstream signaling partners, and the 
role of the pathways in (patho)physiological processes in the brain, with WNT-5A as a 
common nominator. One could say these subjects seem to be far apart from each other, 
however I would rather state they cover a broad spectrum within the field of WNT 
signaling. I believe it is of utmost importance to be able to link pharmacology and 
physiology in order to make progression in the field of drug discovery.  
1.1 WNT/FZD SIGNALING 
1.1.1 Historical overview on discoveries in the WNT/FZD signaling field 
The lipoglycoprotein family of WNTs was first described over 30 years ago by Nusse 
and Varmus (Nusse & Varmus, 1982, Nusse et al., 1991)1, who were at the time 
                                               
1 Nusse and Varmus called the gene initially int1, to denote the first common integration site of the 
MMTV provirus. Around 1990, this nomenclature became inadequate and unworkable due to the 
discovery of several unrelated MMTV target genes that also received the int pronounce. To avoid 
confusion they agreed on naming the original int-1-related genes ‘Wnt’, an acronym combined from 
Wingless-related integration site (Nusse et al., 1991).  
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investigating putative proto-oncogenes in mammary tumors of mice. In hindsight, even 
though they were the first ones to give a full description of the gene, many other groups 
identified members of the WNT family much earlier through (mostly spontaneous) gene 
mutation experiments in different species (Bittner, 1936, Korteweg, 1936). After 
deciphering the sequence and structure of WNT-1 it became clear that the gene starts 
with a signal sequence, revealing its properties as a secretory protein (van Ooyen & 
Nusse, 1984, Fung et al., 1985) and thereby generating the idea that it might serve as an 
extracellular growth factor. Despite the fact that this was of interest for many researchers, 
production and isolation of WNTs was only possible nearly two decades later after the 
discovery that detergents are required to keep the soluble lipid-modified structure of 
WNTs during extraction from cells (Willert et al., 2003, Schulte et al., 2005). Although 
technically challenging, to date all the 19 members of the WNT-family are commercially 
available as recombinant proteins2. The Drosophila int-1 homologue, Wingless, had been 
identified even before the initial experiments on the mammalian counterpart. Mutation 
in the allele resulted in loss of wing tissue (Sharma & Chopra, 1976), revealing the 
importance of these genes in developmental processes. In the late 1980s researchers were 
working on the hypothesis that cancer may origin from cells that have abnormal 
developmental progression, therefore the link between a protein that is involved in cancer 
and embryogenesis was well appreciated. Not surprisingly, WNTs became therefore the 
model protein to study this phenomenon.  Later it appeared that it is not in principle 
mutations in WNTs that cause cancer, but rather the downstream signaling components 
that are generally altered. This resulted in a more complex and challenging field of 
research, meanwhile opening new avenues for the understanding and treatment of 
diseases.  
In the quest to find the putative receptors for WNTs, scientist discovered that in 
fact several groups had been working on one class of receptors for WNTs, the 7-TM FZD 
proteins, however unaware of their connection to WNTs. The earliest reports date back 
to 1944 where the receptor group is described phenotypically in the context of a mutant 
screen (Bridges, 1944). To date, it is generally accepted that FZDs serve as WNT 
receptors and that this interaction can involve the presence of a growing list of WNT co-
                                               
2 However caution should be taken when using them in experimental designs due to the fact that the 
different WNTs may exhibit only partial activity after purification.    
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receptors, e.g. low density lipoprotein receptor-related protein (LRP) 5/6, receptor 
tyrosine kinase (ROR) 1/2 and related to receptor tyrosine kinase (Ryk) (Schulte, 2010). 
1.1.2 Lipoglycoproteins of the WNT family; structure, function and transport 
The lipoglycoprotein family of WNTs consists of 19 members in mammals. WNTs are 
lipid modified and have therefore hydrophobic characteristics (Willert et al., 2003). For 
many years purification of active WNT proteins was challenging, explaining why 
relatively little pharmacological information regarding WNT/FZD signaling is 
published. At the moment all WNTs are commercially available as recombinant proteins, 
creating new opportunities for pharmacologists to better understand receptor-ligand 
kinetics, conformational changes of the receptor upon WNT-binding and activation of 
downstream signaling partners, to name but a few. This information will contribute to 
the development of drug targets in which this pathway plays a role. The level of purity 
and the percentage of active protein after purification however has been a matter of 
concern. For example, Cajanek et al. tested different lots of recombinant WNT-3A and 
discovered that, even though all tested lots activated the WNT/β-catenin pathway, certain 
individual lots activated the phospatidylinositol 3’-kinase/protein kinase B/glycogen 
synthase kinase 3 (PI3/ /GSK3) pathway independent of WNTs (Cajanek et al., 2010), 
raising the question which activation is caused by WNTs and which by impurities in the 
WNT preparation.  
Recently the first crystal structure of a member of the WNT family, Xenopus 
WNT-8 (XWNT8), was described. The authors crystallized XWNT8 in complex with 
the cystein rich domain (CRD) of FZD8. Determination of the WNT8/FZD8 structure can 
lead to a better understanding in which manner WNTs activate FZDs and explain the 
relevance for binding or activation of for example the presence of the CRD on FZDs or 
the lipid modification of WNTs. The structure of WNT8/FZD8-CRD showed two 
important domains of WNT, referred to as the thumb and the index finger that are both 
connected to a central palm domain, interacting with FZD8 CRD at two sites (Site1 and 
Site 2). The complex is formed in such a way that the WNT-lipid is shielded from 
aqueous solvents (Janda et al., 2012). The structural features of the XWNT8 do not show 
any obvious resemblances to any other currently known protein fold. Even though 
clarification of the WNT/FZD-CRD complex provides key information for the 
development of pharmacological agents to modulate the pathway, it also raises more 
questions. Are WNT/FZD combinations selective? Does a conformational change of 
FZD occur upon WNT binding? Where is the place of the coreceptors in the WNT/FZD 
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complex and how do they influence the binding of WNTs? Future structural biology 
experiments will possibly shed light on these issues.  
In the Drosophila wing Wingless (Wg) proteins act as morphogens and exert 
their effect through concentration-dependent gradients reaching target cells from a short 
to long range, thereby induce patterning and cell differentiation. Several studies have 
identified necessary components for the secretion of WNT proteins, such as the 7TM 
cargoreceptors Wntless (EVI/WIs or WLS)3 and the acyltransferase Porcupine. The latter 
is necessary for the addition of a palmitoleic acid to WNT proteins, which is essential for 
secretion (Takada et al., 2006). Another crucial lipid modification that contributes to the 
hydrophobicity of the protein is the palmitoylation on a cysteine residue, a modification 
that is required for the activity of WNTs (Willert et al., 2003, Kurayoshi et al., 2007). In 
which matter WNTs are released and subsequently travel through the interstitial space 
has been of interest for many years. Given the fact WNTs are rather hydrophobic, the 
likelihood that WNTs use cell membranes or carrier proteins for transport is high. 
Recently the hypothesis that active WNT proteins are secreted on exosomes in vivo and 
in vitro has been tested by several research groups. Gross et al. show that WNTs, together 
with Evi/WIs, are transported through endosomal compartments onto exosomes (Gross 
et al., 2012). However, the details on this route of transport remain to be elucidated. 
1.1.3 Frizzled receptors and their downstream binding partners 
FZDs exhibit the typical G protein-coupled receptor (GPCR) features, among which the 
7TM subunit structure. Despite a longstanding redundancy in the field that these receptor 
are indeed coupling to G proteins, several reports from our lab and others have been 
published to date proofing the ability of FZD to transduce heterotrimeric G protein 
signaling (Kilander et al., 2014a, Kilander et al., 2014b, Slusarski et al., 1997a, Slusarski 
et al., 1997b, Katanaev et al., 2005) (paper I). Although FZDs may be able to activate 
G proteins, it is likely that the receptors functions in an atypical manner, and received 
therefore their own class within the Guide to Pharmacology, composed by the IUPHAR 
network (Alexander et al., 2013, Foord et al., 2005). Currently over 40% of the 
medication used in the clinics is targeting G protein-coupled receptor (GPCR) signaling, 
of which one of the most eminent is probably the group of beta-receptor antagonist used 
to decrease hypertension (Lundstrom, 2009). Given the previous and the abundant role 
                                               
3 In Drosophila the gene is called Evi or WIs, the human homologue is called WLS.  
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of WNT/FZD signaling in disease, the answer on why to study the possible involvement 
of G proteins in FZD signaling becomes self-evident.  
The earliest reports on the involvement of G protein signaling in relationship to 
FZDs describes the activation of a WNT/FZD/Ca2+ pathway after injection of RNA 
coding for different WNTs and FZDs in embryos of Xenopus laevis and Danio rerio. 
This activation could be inhibited by the Gαi/o subunit inhibitors pertussis toxin (PTX) 
or through the overexpression of Gα sequestering βγ subunits (Slusarski et al., 1997a, 
Slusarski et al., 1997b). To date, a series of publications show that FZDs indeed couple 
to heterotrimeric G proteins and that this interacting is PTX-sensitive (Sheldahl et al., 
1999, Sheldahl et al., 2003, Kremenevskaja et al., 2005, Dejmek et al., 2006, Ma & 
Wang, 2006, Halleskog et al., 2012, Halleskog & Schulte, 2013a, Katanaev et al., 2005).  
It has been proposed that FZDs - after ligand binding - do not activate heterotrimeric G 
proteins under all circumstances, but that the activation depends on a number of factors 
such as the type of ligand, presence or perhaps absence of certain co-receptors, cell type 
and stage of development (Egger-Adam & Katanaev, 2008, Schulte, 2010). Also the 
presence of the downstream protein disheveled (DVL) could play a role. There are three 
variants known in humans (DVL1, 2 and 3) and they serve as central scaffold proteins 
localized at the crossroad of multiple WNT/FZD pathways (Gao & Chen, 2010). So far 
there is literature showing that the heterotrimeric G proteins could both act upstream as 
well as downstream of the DVL and that this can lead to either β-catenin-dependent and 
–independent pathways (Sheldahl et al., 2003, Liu et al., 2005, Bikkavilli & Malbon, 
2009). Furthermore, the fact that DVL itself can bind to FZDs as well through their 
centrally located PDZ (Psd-95/Disc large/ZO-1) domain, expands the variety of possible 
complex models. In a recent published paper it was demonstrated that two conserved 
motifs, located at the third intracellular loop and the classic C-terminal motif of FZD, is 
required for DVL binding through its DEP and C-terminal domains. This binding is 
crucial for the Wnt-induced β-catenin activation in cultured cells and Xenopus embryos 
(Tauriello et al., 2012). Presumable hypothesis are that DVL and heterotrimeric G 
proteins either (i) compete (ii) cooperate or (iii) bind to different FZD isoforms upon 
ligand binding (Kilander et al., 2014b).  
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1.1.4 Downstream signaling pathways 
Downstream of WNT/FZD stimulation, several different pathways can be activated. 
Historically, the two main signaling branches were divided into canonical and non-
canonical signaling, depending on the involvement of the transcriptional regulator β-
catenin. To date, these branches are named β-catenin-dependent and –independent 
signaling respectively. Most research has been done on the function and regulation of β-
catenin-dependent pathway, since the pharmacological readout for this pathway – 
activation of the luciferase T-cell specific transcription factor/lymphoid enhancer factor 
(TCF/LEF)-driven reporter gene called TOPflash assay - was already well-established 
since 1996 (Molenaar et al., 1996, Van de Wetering et al., 1996), and has proven to be a 
robust assay. Moreover, activation of this pathway can be investigated by several other 
methods such as embryo body axis duplication in Xenopus Laevis, β-catenin stabilization 
by western blot (WB) or immunocytochemistry and transformation of C57MG cells 
(Barker, 2008). The β-catenin-independent pathways encompass several complex 
signaling routes: FZD/planar cell polarity (PCP), WNT/Ca2+, WNT/cyclic adenosine 
monophosphate (cAMP), WNT/ROR, WNT/RAC, and the WNT/RHO pathway 
(Semenov et al., 2007, Schulte, 2010). Due to the diverse and complex nature of these 
pathways, the field suffers from a lack of suitable and robust assays to investigate this 
branch in more depth.  
1.1.4.1 β-catenin-dependent pathway 
As mentioned earlier, the β-catenin-dependent pathway is named after its main player, 
the cadherin-binding and transcriptional regulator β-catenin. Signal initiation happens 
upon the formation of a ternary complex between WNT, FZD and the co-receptor LRP 
5/6, followed by the recruitment of the scaffolding protein DVL. In turn, this complex 
forms signalosomes and triggers the phosphorylation of LRP6 (Bilic et al., 2007). This 
causes a cascade of intracellular events leading to the inhibition of the destruction 
complex consisting of GSK3, axin, adenomatous polyposis coli (APC) among others. In 
the absence of a functional destruction complex, β-catenin stabilizes, accumulates in the 
cytosol and subsequently translocate into the nucleus. There it binds to the transcription 
factors factor TCF and LEF resulting in the regulation of many target genes, such as the 
proliferative genes c-myc and cyclinD1, or inflammatory genes cyclooxygenase 2 (COX-
2) and inducible nitric oxide synthase (iNOS) (Ramsay et al., 2003, Barker, 2008, Du et 
al., 2009, MacDonald et al., 2009, Tetsu & McCormick, 1999). The β-catenin pathway 
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is especially known for its regulatory role in cell growth and differentiation, and is 
therefore actively studied in cancer research, neurodegenerative diseases and stem cell 
research (Moon, 2005).  A schematic overview of β-catenin-dependent pathways is 
shown in figure 1.  
 
 
Figure 1: Schematic view of the β-catenin-dependent signaling pathway. For detailed description see 
text. Abbreviations not mentioned in the text: β-arr, β-arrestin; Gi, inhibitory heterotrimeric G protein; Gq, 
heterotrimeric G protein; CK1, casein kinase; GRK, G protein-coupled receptor kinase; CDK, cyclin 
dependent kinase. Image modified from Schulte et al. 2010. 
1.1.4.2 β-catenin-independent pathways 
The pathways included in this branch all signal independently of β-catenin, therefore they 
are referred to as the β-catenin-independent pathways. However, because this branch 
encompasses several complex signaling routes that can either signal independently, cross 
talk or partially overlap, it would be more appropriate to speak of a network rather than 
a group of pathways. The cellular responses and the ultimate (patho)physiological effect 
in organisms induced by these pathways relate to cytoskeletal rearrangements of cells 
leading to processes such as cell motility, migration, invasion and tissue polarization 
(Schulte, 2010). The most well described pathways are the PCP and WNT/Ca2+ pathway. 
PCP signaling refers to 2-dimensional cellular orientation processes of which for 
example the wing of D. melanogaster and the insect eye have served as models to study 
this phenomenon. In vertebrates similar mechanisms are known as for example 
convergent extension (CE), neural tube closure and hair follicle orientation in the skin 
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(Fanto & McNeill, 2004). Activation of the WNT/Ca2+ pathway results in the increase in 
intracellular calcium followed by the initiation of a number of different cellular functions. 
Calcium has several downstream targets such as nuclear factor of activated T cells 
(NFAT) (Saneyoshi et al., 2002, Dejmek et al., 2006), Ca2+-dependent protein kinase 
(PKC) and Ca2+-calmodulin dependent protein kinase II (CamKII) (Sheldahl et al., 2003, 
Kuhl et al., 2000). Pathway activation is most likely occurring through heterotrimeric G 
proteins. DVL seems to be required for activation as well (Sheldahl et al., 2003), however 
there is also evidence showing that the WNT-5A induced rise in calcium is functional in 
cells depleted of DVL by siRNA (Ma & Wang, 2007).   
1.1.5 Conceptualizing specification and bias in WNT/FZD signaling 
Over history, scientists have attempted to create drugs to improve medical conditions. 
Most drugs consisted of plant extracts that were used based on empirical knowledge. The 
relatively recent discovery of membrane receptors allowed the formulation of molecules 
that targeted specific functions of the cells. This mentality of research has guided 
discovery over the last century. Recently, it has been discussed the possibility that 
different ligands may trigger distinct signal pathways, acting through a single receptor. 
This concept, called “biased agonism”, works with the hypothesis that the 
multidimensional structure of a receptor may be influenced by multiple ligands, greatly 
affecting the different downstream signaling pathways in a receptor conformation-
dependent manner. The WNT/FZD binding specificity, the activation, and the 
involvement of associated cellular components determining the signal outcome have so 
far not been systematically addressed and are therefore poorly understood. This is partly 
due to the fact that only until recently all the existing WNT proteins became 
commercially available in recombinant form. Table 1 gives an overview of the different 
receptor/ligand combinations known so far from the literature.  
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Table 1: WNT/FZD interaction overview. Tabulated the reported WNT/FZD interaction partners. 
Crosses (x) indicate direct binding based on immunoprecipitation data, circles (o) indicate interactions 
proven by experimental evidence such as colocalization, internalization, TCF/LEF activity, red crosses (#) 
indicate interactions based either CRD binding or phosphorylation of β-catenin, DVL or LRP6 as described 
in paper II. (Modified according to (Dijksterhuis et al., 2013). 
 
 
Because of the high complexity of the different signaling pathways that possibly even 
cross talk, it is not known whether certain WNT/FZD signaling pairs can selectively 
activate or prefer certain signaling routes or downstream binding partners above others. 
For future drug discovery studies it is of utmost importance to dissect the signal 
specification of the WNT/FZD pathway. For example, in some case, one might prefer to 
activate solely heterotrimeric G proteins through FZD without affecting DVL. This 
response can be achieved by the development of small molecules that induce a certain 
conformational change of the receptor, resulting in a receptor conformation-dependent 
activation of G proteins. Figure 2 envisions both the challenges and opportunities when 
investigating biased agonism in WNT/FZD signaling.  
 
 
 
WNT 1 2 2B 3 3A 4 5A 5B 6 7A 7B 8A 8B 9A 9B 10A 10B 11 16 
FZD1 x x  o x#  x# o#  o x         
FZD2  o  o o# # x# # o o o  o       
FZD3  x   X  x             
FZD4  x x  o# # o# #   x         
FZD5  o   x# # x# #  x     o  o   
FZD6     X x x o  o          
FZD7     x# # o# #  o          
FZD8     x# # # #       o     
FZD9  x                  
FZD10           x         
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Figure 2: WNT/FZD interaction overview. Schematically visualized the possible WNT/FZD binding 
combinations, the potential activation or binding of various known downstream signaling proteins – DVL 
and Gα-subunits - and the various receptor phosphorylation sites (marked with blue dots). The different 
binding and activation arrangements will determine a so called ‘phosphorylation barcode’ at the c-terminus 
of the FZDs. The question mark indicates the uncertainties in pathway continuation.  
 
1.2 ROLE OF WNT-5A IN BRAIN PHYSIOLOGICAL PROCESSES 
1.2.1 Function, expression and distribution in the central nervous system 
WNT signaling has various functions in the development of the central nervous system 
(CNS), including synaptogenesis, axon growth and guidance and differentiation 
(Inestrosa & Varela-Nallar, 2014a, Inestrosa & Varela-Nallar, 2014b, Inestrosa & 
Arenas, 2010). Members of the WNT-family have different functions in developmental 
processes within the CNS, depending on the WNT-isoform, region of expression and the 
receptor repertoire present in the microenvironment. For example, they can serve as pro- 
or anti-synaptogenic factors in both vertebrates and invertebrates (Inestrosa & Arenas, 
2010, Budnik & Salinas, 2011, Sahores & Salinas, 2011). In-depth research has been 
done on the function of WNT-7A in synapse formation and growth (Hall et al., 2000). 
FZD5 appears to be one of the key receptors mediating this response (Sahores et al., 
2010). WNT-5A has been a WNT-isoform of interest regarding CNS development as 
well. After the first experiments in loss-of-function mutation of WNT-5A, the mice 
showed severe developmental aberrations, among which the inability of the extension of 
the A-P axis. Additionally, truncated limbs as well as outgrowth defects in the face, ears 
and genitals led the authors to conclude that WNT-5A regulates pathways important in 
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extension of structures growing outwards from the primary body axis. This is likely due 
to the fact that WNT-5A regulates proliferation of progenitor cells in the mesoderm, 
shown by the incorporation of the nucleotide analogue 5-bromo-2’-deoxyuridine (BrdU) 
(Yamaguchi et al., 1999). To date, WNT-5A is known to regulate proliferation as well 
as differentiation in neuronal progenitor cells, and has therefore a function in neurite 
development (Yu et al., 2006, Paina et al., 2011). Furthermore, it plays a role in 
dopaminergic axon growth and guidance (Blakely et al., 2011, Castelo-Branco et al., 
2006), has shown to regulate postsynaptic assembly through activation of β-catenin-
independent WNT signaling in neurons (Farias et al., 2009, Cuitino et al., 2010) and 
regulates the clustering of the postsynaptic density protein-95, a protein involved in the 
regulation of AMPA and NMDA receptors (Farias et al., 2009).  
Even though WNT-5A shows to have a plethora of different functions within 
the CNS, little is known about the WNT-5A producing cell and the regional location of 
the protein. This is probably due to the fact that antibodies raised against WNT proteins 
have been of questionable quality and immunohistochemistry stainings turned out to be 
challenging. It has been suggested that glia cells present in the ventral midbrain, but not 
in the cortical region, serve as a source for WNT-5A protein. The WNT-5A secreted by 
these glia cells is responsible for the differentiation of Nurr1-expressing neuronal 
precursor cells into the dopaminergic phenotype (Castelo-Branco et al., 2006).  
A closer look at the WNT-5A in gene expression data publicly available 
through the dataportal of the Allen Developing Brain Atlas (Allen, Developing Mouse 
Brain Atlas, ©2013 ) shows us that the expression in the brain is highest during prenatal 
stage E11.5 and postnatal stage P14 (see Fig 3). Regions of interest are the 
Telencepahalic vesicle (Tel) and the Medullary hindbrain (MH). Seemingly, during those 
stages of maturation, WNT-5A is required for the development of the CNS. Although 
useful data, it does not provide information on the cell type that is expressing WNT-5A.  
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Figure 3: WNT-5A expression in the mouse brain. Heatmap of WNT-5A expression in the mouse brain 
at different stages of development (E11.5 till p28). The abbreviations stand for Rostral secondary 
prosencephalon (RSP), Telencephalic vesicle (Tel), Peduncular (PedHy), Prosomere 3,2 and 1 (p3,2,1), 
Midbrain (M), Prepontine hindbrain (PPH), Pontine hindbrain (PH), Pontomedullary hindbrain (PMH) and 
Medullary hindbrain (MH). Figure modified from the Developing Mouse Brain Atlas (Allen, Developing 
Mouse Brain Atlas, ©2013 ).  
1.2.2 Immunological effects on microglia 
Microglia serve as the immunocompetent cells of the brain and account for 
approximately 10% of the total cell population in the adult CNS (Aguzzi et al., 2013). It 
is generally acknowledged that microglia are not uniformly distributed throughout the 
brain and they consist of several subtypes exerting their own function within 
immunological processes  (Lawson et al., 1990). If microglia have a function under 
normal physiological conditions, or solely comes into play during pathophysiology, 
remains a matter of debate. So far, it is known that microglia continuously sense their 
surroundings in the search for disturbed homeostasis. Upon disturbance of the 
homeostasis within the CNS - due to for example injury or bacterial or viral intrusion - 
microglia act as immune regulators upon which multiple signaling cascade are activated. 
Following the initial activation response, release, transcription and expression of several 
proteins are initiated leading to proliferation and invasion of microglia and phagocytosis 
of bacteria and debris. Key immune modulators involved in this process are the groups 
of cytokines and chemokine (-receptors), major histocompatibility complex II, cluster of 
differentiation proteins, matrix metalloproteinases (MMPs) and iNOS (Kettenmann et 
al., 2011). Inflammatory responses by microglia are not uniform and can strongly depend 
on the type of trigger or the receptor repertoire present on the cells. Traditionally, 
responses were divided into pro- and anti-inflammatory, also referred to as ‘classical’ 
M1 and ‘alternative’ M2 morphological types. However, to date a more complex model 
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of several ‘in-between’ inflammatory stages is suggested, which exert and prefer 
different functions within the scope of immunological responses (Gertig & Hanisch, 
2014, Eggen et al., 2013). 
A classical way to study activation of microglia in culture is by stimulating the 
cells with lipopolysaccharide (LPS), a compound normally found in the bacterial wall of 
gram-negative bacteria. Microglia express the LPS receptor Toll-like receptor 4 on their 
cell membrane, and are therefore capable to recognize it as a foreign compound, resulting 
in acquirement of a proinflammatory phenotype. Upon binding, microglia will release or 
induce several proinflammatory substances such as tumor necrosis factor alpha (TNFα), 
COX-2), interleukin-6 (Il-6) and nitric oxide (NO) (Hanisch & Kettenmann, 2007). A 
shortcoming of this method is that it only initiates one type of pro-inflammatory 
response, which does not reflect the effect in a pathological condition. In the search for 
a better understanding on how microglia exert their function in vivo, studying this cell 
type in their natural milieu would be preferred.  
WNTs have been associated with an array of immunological processes in the body, 
however their precise role is not fully delineated. For example, WNT-5A and FZD5 are 
increased in synoviocytes in rheumatoid arthritis (Sen et al., 2000) and synoviocyte 
activation is suppressed upon blockage of the WNT-5A/FZD5 pathway (Sen et al., 2001). 
Additionally, genetic variations within WNT signaling components play a role in the 
initiation and maturation of neurodegenerative diseases such as autism, Alzheimer’s 
disease (AD), schizophrenia and Parkinson (De Ferrari & Moon, 2006). The combination 
WNT-5A/FZD5 is upregulated in AD mouse brain as well, suggesting WNT-5A 
signaling is aberrantly activated during AD pathogenesis (Li et al., 2011). A study from 
our lab showed β-catenin accumulation in microglia undergoing a proinflammatory 
morphogenic transformation in human brain material, a phenomenon likely to occur in 
areas undergoing neuroinflammation such as AD (Halleskog et al., 2011). Furthermore, 
in vitro analysis revealed both WNT-3A and WNT-5A as inducers of a proinflammatory 
response in primary mouse microglia. This was shown by several experiments including 
the increase of multiple proinflammatory cytokines, chemokines and innate immune 
response factors (Halleskog et al., 2012, Halleskog et al., 2011). However, both WNTs 
did also counteract LPS-induced expression of proinflammatory components COX2, IL-
6 and TNF-α, suggesting they serve as homeostatic regulators for microglia regarding 
immunological functions (Halleskog & Schulte, 2013b).  
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1.3 GLIOBLASTOMA MULTIFORME 
1.3.1 Introduction to glioblastoma pathogenesis 
Glioblastoma multiforme (GBM) are the most frequently diagnosed and lethal primary 
tumors in the CNS, with a median survival of approximately one year (Ohgaki & 
Kleihues, 2005). GBMs are ranked by the World Health Organization classification 
scheme as stage IV tumors within the group of gliomas, a classification based on severity 
(stage I-IV) (Louis et al., 2007). Treatment options are limited and the standard entails 
currently surgical resection (Rostomily et al., 1996, Chang et al., 2003), followed by 
radiation therapy (Burton & Prados, 2000, Castro et al., 2003) and the chemotherapeutic 
drug Temozolomide (Temadol®) (Burton & Prados, 1999, Castro et al., 2003). In essence 
however, they are incurable. Despite significant efforts to improve GBM models to study 
this disease, very little progression has been made in the development of new therapeutic 
agents against this devastating disease. In fact, the median survival has not changed 
considerably in almost a century (Bailey C, 1926).  
Gliomas commonly consist of a heterogeneous cell population derived from a 
combination of cancer cells with random mutations, as well as a large group of infiltrating 
brain cells from diverse origin. A popular hypothesis on the propagation of the tumor, 
supported by a growing body of evidence, entails the presence of a cancer stem cell 
(CSC) population within the tumor. The CSCs share features with somatic stem cells, 
showing self-renewing behavior and thereby allowing the tumor to grow (Lathia et al., 
2011). This would also explain the ability of tumors to resist and evade both the body-
own immune attack on the tumor as well as therapeutic intervention. The acquired 
knowledge on the presence of CSCs within the tumor adds a challenge to study tumor 
biology ex-vivo, given the fact that employing serum-cultured cell lines derived from 
clonal expansion simply do not suffice. To map the tumor behavior employing the use of 
a full repertoire of cells present in the tumor appears to be a necessity. Together with the 
increased interest in CSCs, the cellular origin of primary malignant gliomas becomes of 
point of attention.  
Based on histological features, gliomas can be classified in three main types: 
astrocytomas, oligodendrogliomas and mixed oligoastrocytomas (Louis et al., 2007). 
Within these subtypes further stratification are made upon tumorigenic properties, such 
as the presence of necrosis, mitosis and a vascular network, which define the grade of the 
tumor (WHO grade I-IV). Even though this classification system does give insight in the 
aggressiveness and clinical course of gliomas, the variability in biological behavior 
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within the different grades cannot be explained by this scheme. Due to the high 
complexity of these tumors and the inability to predict patient outcomes based on 
histopathological features, the search for a more accurate classification system is crucial.  
As a result of the growing field of molecular genetics, Verhaak et al. published recently 
a hallmark paper introducing a new classification system for GBMs alone, entirely based 
on gene-expression profiles of tumors. The authors employed sequence data of a large 
GBM cohort (n=206 patients) generated and provided by The Cancer Genome Atlas 
(TCGA) Research Network. Gene expression and alterations of EGFR, NF1 and 
PDGFRA/IDH1 define the subtypes, respectively Classical, Mesenchymal and Proneural 
(Verhaak et al., 2010). The fourth subtype, Neural, was typified based on the expression 
of typical neuronal markers such as NEFL and GABRA1. The four subtypes show 
similarities with various neural lineages and respond differently upon chemotherapy, 
making it possible to clinically predict patient survival after therapy.  
GBM are thought to arise from either preexisting lower-grade tumors (secondary GBM) 
or as primary tumors, emerging de novo (Ohgaki & Kleihues, 2005, Scherer, 1940). The 
quest to find the tumor initiating cells has been ongoing for over 150 years already and 
continues to be a matter of debate. The three mainstream hypothesis are based on: (i) the 
embryonic displacement theory postulated by Virchow in his book Cellular pathology in 
1858 (Virchow, 1858), (ii) the idea that gliomas arise from the subependymal zone (first 
phrased by (Globus, 1944) (iii) or from astrocytes (Levy et al., 2009). Even though 
opinions about the cellular origin of gliomas have been going back and forth throughout 
history, with today’s knowledge we know that these three hypothesis do not necessarily 
contradict. The cancer stem cell hypothesis (Huntly & Gilliland, 2005) would explain the 
initiation by (i) ‘embryonic tissue’ (Virchow) due to the presence of stem cells (ii) the 
origin of gliomas in the subependymal zone due to the observation that most gliomas 
exist in or close to the SVZ, proven to be a harbor for stem cells in the brain and (iii) the 
fact that astrocytes arise from the SVZ stem cells (Siebzehnrubl et al., 2011).   
Gliomas consist of, besides the tumor cells, multiple other cell types often 
referred to as ‘tumor-associated cells’. For example neuronal precursor cells, vascular 
cells, microglia and peripheral immune cells.  The cellular composition of the glioma 
plays a crucial role in the course of the pathology. The majority of tumor-associated cells 
are microglia, the macrophages of the brain (Charles et al., 2011). The stromal cells of 
gliomas play part in the pathology and are therefore interesting to target by therapeutic 
agents. For example, recruitment of pericytes and vascular smooth muscle cells are 
crucial for the establishment of the vascular tree and promoting angiogenesis, processes 
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essential for the survival and growth of the tumor (De Palma et al., 2005, Song et al., 
2005). Targeting HIF-1α, a protein (partially) responsible for the recruitment of pericyte 
progenitor cells in gliomas (Du et al., 2008), can indirectly prevent the formation of new 
vessels in and surrounding the tumor and thereby inhibit tumor growth. Furthermore, the 
ability of astrocytes to promote GBM cell invasion through the activation of pro-MMP2 
(Le et al., 2003) and the production of neurotrophic factors such as Transforming growth 
factor alpha and C-X-C motif chemokine 12  (Hoelzinger et al., 2007) makes them 
worthwhile to investigate for future therapy. However, due to the fact they do not 
proliferate, have proven to be inherently resistant to cytotoxic therapies, and serve 
probably no critical function within the tumor they are not a preferred study object. 
Additionally, drugs targeting for example PI3K, notch and sonic hedgehog signaling 
pathways – critical pathways activated in the perivascular niche of the tumor -  are 
already clinically implemented or under development (Charles et al., 2011). However, 
even though the stromal niche seems to be an interesting target for drug therapy, a 
cautionary note should be taken concerning resistance to treatment specifically controlled 
by the tumor microenvironment. New studies demonstrate that microenvironment-
derived resistance can alter the effectivity of drugs, and therefore a combination 
treatments targeting both the cancer cells as well as cells from the tumor 
microenvironment is probably most beneficial (Ostman, 2012). A more recent and 
rapidly emerging field regarding treatment focusses on immunotherapy, an approach that 
has already been proven to demonstrate clinical benefit for other cancers. Examples of 
such therapies that are FDA approved and currently used in clinics are the humanized 
monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (Ipilimumab) (Hodi et 
al., 2010), and the dendritic cell cancer vaccine (sipuleucel-T) (Kantoff et al., 2010). 
GBMs are capable to avoid endogenous anti-tumor immune response, by generating a 
local immunosuppressive shield through the secretion of immunosuppressive factors 
such as tumor growth factor-β (TGF-β) (Constam et al., 1992) and interleukin-10 (IL10) 
(Huettner et al., 1995). Additionally, the systemic immune attack is also inhibited 
through impairment of T cell function and an increased T regulatory infiltration (Waziri, 
2010). Given the previous, considerable achievements can be made with an 
immotherapeutic approach against GBMs. However, the current understanding on how 
GBMs foster immunotolerance is limited and therefore more research on the subject is a 
precondition for future successes in this type of therapy.  
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1.3.2 Glioma-associated microglia 
Up to 30% of the tumor mass can consist of resident, ramified tumor associated microglia 
(Hanisch & Kettenmann, 2007), which was initially published already in 1925 (Penfield, 
1925). The author, Wilder Penfield, used silver carbonate staining to detect the microglia 
within human gliomas samples and describes his finding as follow: “(..) these cells 
(microglia) are found to be plentiful in zones encircling the foci of tumor softening.”, 
recognizing the fact that a large part of the tumor consist of microglia. Furthermore, the 
author states that microglia cells are ‘in active dendrophagocytosis’, referring to the 
phagocytic function of microglia (Penfield, 1925). 
Microglia can be present in the brain in different immunological states, 
depending on their environment and the role in (patho)physiological processes they 
employ. Their morphology ranges from a ramified phenotype, with a small body and 
multiple branches, to a more amoeboid-like shape, enabling them to migrate and invade 
throughout the neuronal tissue. The ramified phenotype was historically described as a 
resting state, but now it is generally accepted that these microglia are however actively 
surveying their surroundings. They do so by continuous rebuilding their fine processes, 
allowing scanning of their surroundings for potential disturbed homeostasis. Therefore 
the term of ‘surveying microglia’ is more appropriate. The amoeboid-like phenotype is 
often referred to as the ‘active’ microglia, exerting functions as migration, phagocytosis, 
release of chemoattractive factors and antigen presentation to T cells to assist the adaptive 
immune system. Microglia can be triggered to transform from the surveying state to the 
activated state by external stimuli caused by for example cellular damage or the presence 
of foreign molecules. Between the surveying and active state, microglia can display many 
‘intermediate’ and distinct phenotypes depending on the external stimuli and the 
situational context (Hanisch & Kettenmann, 2007, Eggen et al., 2013, Gertig & Hanisch, 
2014, Kettenmann et al., 2011).  
Even though the main function of microglia is to induce an immune attack against 
cells or pathogens disturbing the homeostasis in the brain, they are not able to perform 
this task within gliomas. On the contrary, several reports have suggested that microglia 
promote gliomas migration and tumor growth, favoring the tumor rather than a healthy 
condition (Bettinger et al., 2002, Zhai et al., 2011, Markovic et al., 2005). Nonetheless, 
major histocompatibility class II (MHC Class II) molecule expression is seen on 
microglia within glioma tissues (Proescholdt et al., 2001, Tran et al., 1998), suggesting 
immunoreactivity against the tumor. However, proper antigen presentation for cytotoxic 
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and helper T cell seems to be deficient, probably due to a lack of expression of co-
stimulatory factors necessary for the activation of T-cells (Flugel et al., 1999). Attempts 
to interfere with the glioma-microglia interaction by using cyclosporine A (CsA) showed 
encouraging results in vitro and in vivo. CsA impaired the protumorigenic phenotype of 
microglia and thereby reduced the activation and invasion of glioma cells (Sliwa et al., 
2007, Gabrusiewicz et al., 2011).   
1.3.3 WNT signaling in glioblastoma 
To date, little research has been done on the role of the WNT signaling pathway in the 
course of glioma pathology. Initial reports show a relationship between typical β-catenin-
dependent signaling pathway activation and GBMs. For example, inhibiting GSK3β by 
lithium chloride, induces cell differentiation and inhibits neurosphere formation in 
human GBM ex vivo cell cultures (Korur et al., 2009). Furthermore, DVL2 is 
overexpressed and is responsible for proliferation and differentiation of both cultured 
human glioma cell lines as well as patient-derived glioma cells. In the same study the 
authors show that by depleting DVL2 in GBM cells injected intracranial in 
immunodeficient mice, the tumor formation is inhibited compared to control (Pulvirenti 
et al., 2011). Recently, more studies start to focus on the role of WNT-5A different 
processes of the tumor and its microenvironment. Initial studies showed that WNT-5A 
induces glioma cell proliferation (Pulvirenti et al., 2011) and is associated with 
infiltrative activity through the expression of MMP-2 in human gliomas (Kamino et al., 
2011). Furthermore, the co-receptor Ryk showed to be an essential protein for the WNT-
5A-dependent invasiveness in human gliomas (Habu et al., 2014). Although recently 
several studies were published showing a potential role of WNT-5A in GBM, the link 
between WNT-5A, GBMs and the relationship to immunological processes has so far 
not been investigated in detail. 
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2 SPECIFIC AIMS 
The general aim of this thesis is to address the role of WNT/FZD signaling in brain physiology 
and disease and to dissect the molecular features of the pathway important for future use in 
drug development. The specific aims following the general aim were based on the reflections 
described in the introduction and are as follow: 
1. To determine whether WNT-5A can induce activation of heterotrimeric G protein. 
 
2. To assess functional selectivity of WNT-FZD signaling by characterizing binding 
selectivity and activitation of specific downstream signaling pathways. 
 
3. To characterize the WNT-5A mediated proinflammatory response in microglia and to 
further dissect the WNT-5A induced intracellular signaling network.  
 
4. To map WNT-5A distribution and define the WNT-5A-expressing cell type in the 
mouse CNS 
 
5. To identify the role of WNT-5A on the migration and the integration of neuronal 
precursor cells from the subventricular zone, via the rostral migratory stream, towards 
the olfactory bulb. 
 
6. To validate the presence of WNT-5A in GBM and further elucidate the effect of WNT-
5A in the glioma cellular milieu with focus on immunological processes.  
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3 MATERIAL & METHODS 
For this thesis a range of well-established techniques have been used which are listed in table 
2. A description of these standard methods is displayed in the material and method sections of 
each paper and will therefore not be further discussed here. Solely methodological 
considerations relevant for the studies will be described in this section. 
Table 2: Techniques employed in this thesis. 
Method Paper 
Cell culture propagation I-IV 
Isolation and culturing of primary microglia from mice III 
Cell membrane isolation I 
[γ-35S]-GTP assay I 
DNA (stable) transfection methods of cells I, II 
Native-PAGE immunoblotting I 
SDS-PAGE immunoblotting I-IV 
RNA extraction and cDNA synthesis I-IV 
Reverse transcriptase and quantitative PCR I-IV 
WNT/ FZD CRD-Fc binding assays with Biolayer 
Interferometry (BLI) 
II 
Immunoprecipitation I 
Immunocyto- and histochemistry III-V 
Inhibitor treatment/WNT-stimulation I-III 
Mesoscale for TNFα III 
[Ca2+]i imaging III 
cAMP measurements III 
Collagen invasion assay III 
MTT-assay I, III 
Cell counting I, III 
EdU IP injections in mice IV 
WNT-5A heterozygous mouse model IV 
Super resolution/Confocal/fluorescent microscopy III-V 
The Cancer Genome Atlas investigation on GBM dataset V 
Bioinformatical tools: DAVID, Cytoscape, MIMi, MCode, C-
bio portal, GSEA and Oncomine 
V 
Affimetrix gene array  V 
3.1 ASSAYS TO ADDRESS G PROTEIN ACTIVATION  
In paper I we employed the GTPγS assay to quantify G protein activation. In this method the 
exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) measured 
through the accumulation of non-hydrolysable gamma-labeled GTP, occurring after 
stimulation of an appropriate ligand (Harrison & Traynor, 2003). This effect is believed to be 
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the first receptor mediated-event after receptor activation. The characteristics of the GTPγS 
assay are schematically visualized in the figure below.   
 
Figure 4: Schematic overview on GTPyS assay for WNT/FZD interaction. See text for the details.  
 
A description of the assay, presuming WNTs are inducing the exchange through FZDs, is as 
follow: (I) The 7TM units of FZD are imbedded in the lipid membranes of cells and are 
believed to be either precoupled to inactive heterotrimeric G proteins bound to GDP (Kilander 
et al., 2014b, Kilander et al., 2014a) or in close proximity to. After WNT-5A binding to FZDs, 
a conformational change of the receptor occurs resulting in (II) the activation of the intracellular 
G proteins through the exchange of GDP for GTP at the Gα-subunit. (III) After activation of 
the G protein, dissociation of the Gα and Gβγ subunit follows upon which they can interact 
with effector systems. FZD is thought to return to its previous conformational state, making it 
more conceivable for the binding of inactive G proteins. (IV) GTPases reform the Gα-GDP 
binding, allowing Gα and Gβγ to form a heterotrimer. In a GTPyS assay, a non-hydrolysable 
and radioactive form of GTP binds to the active Gα subunit, allowing accumulation of the 
complex in the system. The accumulation of Gα-GTPyS can be measured with a beta counter 
(Harrison & Traynor, 2003).  
An alternative method to measure G protein activation used in study I entails antibody-
recognition of GTP-Gαi with immunoblotting under native conditions. The antibody 
recognizes solely the activated form of Gαi – the form that is bound to GTP - and became 
recently commercially available. Native conditions are required since denaturation of the 
complex will disrupt the binding between Gαi and GTP (Lane et al., 2008).  
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3.2 INVASION ASSAYS 
There are several established methods to measure cellular invasion and migration in vitro. This 
type of assays are clinically most relevant in cancer research determining motility of cancer 
and stromal cells. MMPs belong to a group of proteins known to break down the extracellular 
matrix (ECM), a key process of for example primary tumor cells initiating a metastasis (Hadler-
Olsen et al., 2011). Migration assays occur on 2D surfaces, as the goal is to show directional 
cell movement mimicking the in vivo situation where cells migrate within or between different 
organs. The invasion assays take place on obstructive services such as collagen networks or 
matrigel, representing the in vivo situation in which cells have to modify and interact with the 
ECM to be able to show directional movement (Kramer et al., 2013). Within the term of 
invasion are therefore several processes enclosed, such as adhesion, morphological changes, 
migration and proteolysis of the ECM (Friedl & Wolf, 2010). In paper III, we performed a 
collagen I invasion assay with primary mouse microglia cells. Since we were interested in the 
migratory effects of WNT-5A on microglia – in relationship to the pro-inflammatory and 
proliferative features shown in other experiments - we decided upon an invasion assay rather 
than migration assay. After solidification of the collagen matrix on a glass bottom plate, 
fluorescently labeled microglia are seeded on top of the matrix and WNT-5A is subsequently 
added to the growth medium. The labeling of cells was done with cell tracker red CMTPX dye. 
This dye passes freely through the cell membrane and then becomes cell-impermeant due to 
transformation processes within the cell. It is proven to have low cytotoxicity and will therefore 
not affect cell viability or proliferation. Furthermore it allows for multigenerational tracking of 
cellular movement and has signal retention for more than 72 hours. After allowing the 
microglia to invade for 24 hours, a 3D image stack with the confocal was taken to visualize the 
location of the microglia within the collagen matrix. Analysis was done with the spot-function 
in the Imaris software, defining every fluorescent signal within a certain range as one cell. To 
improve the representation of this assay with the in vivo situation, one could think about 
mechanisms to generate a WNT gradient within the matrix. This however is challenging due 
the fact that WNTs move freely in liquids. Furthermore, co-culture experimentation with other 
cell types present in the brain would give a better overview on the interaction interplay between 
different cell types in the brain. However, this would also complicate the study set-up.  
3.3 USE OF MOUSE PRIMARY MICROGLIA  
In paper III we used primary mouse microglia to study the inflammatory potential of WNT-
5A. Even though the use of cultured cell lines showing microglia-like features, such as N13, 
would be more practical, it is also less physiologically relevant to study. For the preparation of 
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the primary microglia newly born (P1-3) C57BL6 mouse pups were used housed in our animal 
facility at the Department of Physiology and Pharmacology, Karolinska Institute. 
Experimentation was done according to ethical permit N144/08 and N436/10; local ethical 
committee Stockholms Norra Djurförsöksetiska Nämd. A detailed description of the procedure 
is given in Paper III. Microglia were harvested through gentle agitation of the bottle, allowing 
the cells to separate from the astrocytic monolayer for a maximum of three times per batch. To 
determine the contamination of astrocytes in our microglia preparation, we employed an 
immunocytochemistry experiment using fluorescein isothiocyanate (FITC)-conjugated 
Griffonia simplicifolia isolectin B4 or anti-CD11b for microglia staining combined with the 
astrocytic marker anti-GFAP (glial fibrillary acidic protein). The purity of the preparation was 
validated >95%.   
3.4 THE CANCER GENOME ATLAS SEARCH AND ASSOCIATED DATABASES 
The cancer genome atlas is a community research project providing genomic data from at least 
200 different types of cancer. This freely available data is accessible through the TCGA Data 
Portal and the Cancer Genomics Hub and was founded in 2006 by National Cancer Institute 
and National Human Genome Research Institute. Biospecimens are collected after asking 
patients to donate part of their tumor tissue that had been removed in accordance to their 
treatment schedule, as well as samples from normal tissue such as blood. Subsequently the 
biospecimens have to meet a stringent set of criteria concerning the quality of the DNA and 
RNA before they undergo a complete genomic characterization and analysis. All the data is 
coded, meaning the sample information cannot be connected to the patient’s private 
information. The overarching goal of the atlas is to improve the ability to diagnose, treat and 
prevent cancer. By gaining a better understanding on the genomic alterations in cancers, new 
treatment options related to personalized medicine can be in reach.   
Following the release of the data portal of the TCGA, different platforms launched 
websites and software that can be used to interpret the genomic information. For example, in 
paper V we used a set of platforms including: Gene set enrichment analysis (GSEA) 
(Subramanian et al., 2005, Mootha et al., 2003), DAVID (Huang da et al., 2009b, Huang da et 
al., 2009a), Oncomine (Rhodes et al., 2004), Cytoscape (Saito et al., 2012) with the plugins 
Mimi (Jayapandian et al., 2007, Tarcea et al., 2009) and MCode (Bader & Hogue, 2003) and 
c-Bio portal (Cerami et al., 2012, Gao et al., 2013). The GSEA focuses on sets of genes that 
share common biological functions, chromosomal location or regulation. The C-bio portal 
provides the opportunity to explore the genomics across different cancer types through 
visualizing and analyzing genes, samples and data types. The portal also provides exploration 
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in biological pathways, mutual exclusivity or co-occurrence analysis between genes of interest 
and survival curves. Cytoscape allows network data integration, analysis and visualization of 
complex networks. 
3.5 THE USE OF WNT-5A HETEROZYGOUS MOUSE MODEL 
The heterozygous mouse model used in paper IV, was first described in Yamaguchi et al., 1999. 
It was created as follow: A targeting vector with neomycin positive (PGK-neo) and a thymidine 
kinase negative (MC1tk) selection markers was used to disrupt exon 2 at codon 31. The null 
mice are created by electroporation of the construct into AB1 embryonic stem cells. Resistant 
colonies were isolated, expanded and injected into day 3.5 blastocytes of the C57BL/6 strain 
(Yamaguchi et al., 1999). Even though studying a homozygous adult phenotype would give us 
better understanding on the role of WNT-5A on neuronal migration, the mice are perinatal 
lethal due to respiratory failure at birth. Furthermore, the homozygous WNT-5A-null embryos 
show severe shortening of the body and limbs, truncated facial features and loss distal structures 
such as the tail. There is not much literature published on the heterozygous phenotype, except 
some reports on the double heterozygous Wnt5a+/− combined with other mutations, such as 
for example LPR6 (Bryja et al., 2009). Another possibility to study the function of WNT-5A 
in the brain would be by generating a doxycycline-inducible GFAP-CreERT/WNT-5A-loxP 
mouse. This animal model allows to dynamically regulate astrocyte expression of WNT-5A in 
adult mice. Because our results show that WNT-5A is mostly secreted by GFAP+ cells, it would 
be interesting to see what the function is of WNT-5A produced by this astrocyte population.  
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4 RESULTS & DISCUSSION 
4.1 WNT/FZD BINDING, SELECTIVITY AND ACTIVATION OF 
DOWNSTREAM SIGNALING PARTNERS 
4.1.1 Activation of heterotrimeric Gαi2/3 proteins by WNT-5A in the microglia like cell 
line N13 (Paper I) 
FZDs have recently been grouped in a separate class within the superfamily of GPCRs by the 
IUPHAR and The British Pharmacological Society in The Guide to Pharmacology (Alexander 
et al., 2013, Foord et al., 2005). For many years however, the coupling of heterotrimeric G 
proteins to FZDs has been a matter of debate. Even though the general opinion is shifting at 
present towards FZDs signaling as bonafide GPCRs (Schulte & Bryja, 2007, Schulte, 2010), 
there are opponents arguing the importance of this coupling for the activation of downstream 
signaling components. In this article we investigated if WNT-5A is able to induce G protein 
activation in cell membranes of the microglia like cell line N13 at endogenous expression levels 
of relevant signaling components. We employed a [γ-35]GTP assay, established over three 
decades ago for β-adrenergic receptors (Asano et al., 1984) and muscarinic receptors (Kurose 
et al., 1986). In this assay the accumulation of Gα-GTP is measured, which is induced by 
agonist occupation of GPCRs followed by the exchange of GDP for GTP at the α-subunit 
(Harrison & Traynor, 2003). This response is seen as the first event after stimulation of a 
GPCR, and therefore used as a method to study GPCRs activity. In this article we show a WNT-
5A mediated exchange of GDP for GTP in a microglia-like cell line. To our knowledge, this 
was the first report to describe such an event using physiological G protein and FZD levels.  
First we investigated WNT-5A induced proliferation in the microglia-like cell line 
N13. Proliferation is a physiological relevant event in microglia, occurring after microglia 
undergo the transition from the surveying towards the activated state. In case of an 
inflammatory response, microglia migrate towards the site of action and proliferate to be able 
to perform their intrinsic function properly. We showed that N13 cells proliferate upon WNT-
5A stimulation and that this stimulation is sensitive to the Gi/o inhibitor PTX, revealing a role 
for Gi/o proteins in this response. Even though one could question the relevance of this assay 
with the use of an immortalized cell line, a later study from our lab showed a similar effect in 
primary mouse microglia after WNT-5A stimulation (Paper IV).  
Even though we now had initial proof that WNT-5A can induce G protein related 
effects in our cell line, we were further interested if we could detect a direct interaction between 
FZDs and G proteins. Therefore we employed a [γ-35]GTP assay, resulting in the discovery of 
dose-dependent and PTX sensitive WNT-5A activation of the GDP for GTP exchange at the 
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α-subunit (see figure 5 A and B). It is therefore likely to assume that WNT-5A can activate G 
proteins through FZDs, and that this response is dependent on the Gαi subunit.  
 
 
 
 
 
  
 
 
 
The biphasic dose-response curve (figure 5A) differs from a sigmoidal dose-response curve as 
one expects from a classical ligand/receptor response. It is known that WNT-5A can bind to 
several FZDs (Dijksterhuis et al., 2013), which could lead to opposing responses resulting in 
the biphasic effect. Additionally, WNT binding to Heparan sulfate proteoglycans, proven to be 
necessary for the maintenance of the solubility and thereby the stability and activity of WNTs 
in mammalian tissues (Fuerer et al., 2010), might distort the classical sigmoid relationship.  
To further substantiate the finding that WNT-5A can induce G protein activation from 
the Gi/o family, we performed immunoblotting experiments with an antibody selectively 
recognizing the active form of Gi/o (Gi-GTP antibody) and tested this in both N13 cell 
membranes and permeabilized cells. The positive result of this experiment was in agreement 
with the earlier findings from [γ-35]GTP assay, strengthening the hypothesis that WNT-5A can 
induce G protein activation. qPCR experiments revealed the FZD expression profile in N13 
cells as follows: FZD5>FZD7>>FZD2>FZD4>=FZD9>FZD8. The FZD5 expression is 3 times 
higher than the FZD7 and it is therefore likely to assume that the G protein activation is 
transduced through FZD5. Further investigation by western blot analysis of WNT-5A 
stimulated FZD5 showed a mobility shift on the SDS page, suggesting that a portion of the 
receptors get phosphorylated after activation. If and how this specific interacting induces G 
protein activation remains to be elucidated.    
  
A B
Figure 5: WNT-5A evokes a GDP/GTP exchange in Gi/o α-subunits in membranes of N13 cells.  
(A) A dose dependent activation of G proteins by WNT-5A (300 ng/ml) measured by the incorporation of  
[γ-35]GTP. (B) The WNT-5A induced G protein activation is PTX sensitive (100 ng/ml, incubation overnight). 
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4.1.2 Analysis of WNT/FZD interactions and their functional selectivity (Paper II) 
The puzzling thought that mammalians have 19 different WNTs, 10 different FZDs, as well as 
several associated downstream signaling networks inspired us to investigate WNT/FZD 
binding pairs and explicit downstream activity systematically. In order to do so, we employed 
the myeloid progenitor cell line 32D, which has the unique feature of a complete lack of 
endogenous FZD expression. This enabled us to introduce specific FZD genes and thereby to 
study WNT-induced activation of FZDs individually.  
Here we used Biolayer Interferometry (BLI) to assess WNT/FZD-CRD binding 
partners of WNTs. For this experiment, recombinant CRD proteins of the related FZDs were 
used. Although measurement of binding between WNT and the full length FZD protein - not 
just the CRD domain - would be more biologically relevant, it is so far experimentally not 
possible. In most GPCRs binding assays to full length receptors are straight-forward. However 
for FZDs the method is not established yet, leaving us to rely on the biochemical analysis of 
the WNT/FZD-CRD interaction. WNT binding experiments have been challenging to perform, 
partially due to the fact that most cellular systems express several isoforms of FZDs and a 
suitable systems to study is lacking so far. Furthermore, WNTs have a very high unspecific 
binding to the extracellular matrix of the cell membrane because of their lipid modifications, 
making it difficult to measure binding affinities. The advantage of the biochemical WNT/FZD-
CRD interaction measurement is that with certainty the direct binding affinity between WNTs 
to CRDs can be determined, excluding interference from other receptors. Furthermore, it 
provides accurate affinity measurement outcomes, enabling quantitative comparison between 
the different WNT/FZD pairs.  
 
 
 
 
 
 
 
 
 
Figure 6. WNT/FZD-CRD bioloayer interferometry. (A) Representative binding affinity curve for WNT-5A  
to FZD1-CRD (B) Tabulated the summary of WNT/FZD-CRD binding data shown as: - no binding, + very weak 
binding (> 100 nM), ++ weak binding (40-100 nM), +++ intermediate binding (10-40 nM), ++++ strong binding 
(< 10 nM). NQ stand for weak binding, not quantifiable due to narrow response signal window in the binding 
curves. WNT-7A, -9B, - 10B, -11 and FZD10 show no detectable binding to respectively any of the chosen FZD- 
CRD’s or WNTs in this study (data not shown).   
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Even though it is possible to define binding affinities between WNTs and FZDs, one cannot 
assume this binding transduces an effect downstream and induces subsequently a physiological 
relevant response. Therefore, we investigated several relevant downstream events including the 
phosphorylation of the signaling components DVL2/3 and LRP-6 and the accumulation of β-
catenin.  
DVLs stand on the cross road between various WNT/FZD activation pathways and 
their stimulation requires phosphorylation. This can be visualized on a western blot as a 
electrophoretic mobility shift and is referred to as phosphorylated and shifted DVL (PS-DVL). 
It is known that the isoforms of DVL (1,2, and 3) have considerable overlap in function, 
however there is evidence for functional specification as well (Dillman et al., 2013). In this 
study we show that 32D/FZD2/4/5 cells stimulated with various WNTs show differential effects 
on PS-DVL2 and PS-DVL3, depending on the WNT/FZD pair present. This result points 
towards the hypothesis that the signaling route exhibits functional selectivity.   
We hypothesize that certain biological relevant WNT-receptor complexes could 
transduce β-catenin-independent signaling in the absence of LRP5/6, but on the other hand may 
feed into the β-catenin pathway by forming a complex with LRP5/6 (Kilander 2013, 2014). 
These hypothetical complexes may exist in parallel, opening the possibility that certain WNTs, 
for example WNT-3A, can activate both the heterotrimeric G protein-dependent ERK1/2 
phosphorylation independent of β-catenin as well as accumulation of β-catenin (Halleskog & 
Schulte, 2013a). It is likely to assume that WNT/FZD binding affinity as well as functional 
selectivity plays a role in this.  
In agreement with the literature, WNT-3A induced phosphorylation of LRP6 through 
FZD2,4,5 in this study. The possibility exists that a given WNT will interact with FZD but does 
not activate β-catenin signaling. On the contrary, it might inhibit β-catenin signaling or 
transduce a signal through FZDs that are independent of β-catenin. Thus, with the presence of 
LRP5/6 in the 32D system, one could identify specific FZD complexes that require LRP5/6 for 
signaling. Interestingly, WNT-9B did not show any activation of the assays tested in this study. 
However, previous reports have shown that WNT-9B can bind LRP5/6 and can either activate 
the β-catenin-dependent signaling (through TOPflash) (Bourhis et al., 2010, Gong et al., 2010) 
or the β-catenin-independent signaling pathway (Kilander et al., 2011b), depending on the cell 
type. Therefore, the role of WNT-9B interacting with LRP5/6 for signal specification remains 
to be elucidated.  
This paper contributes to the understanding of the underlying mechanisms that 
determine signal specification by WNTs in FZDs. The beauty of the cellular system of choice 
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entails the presence LRP5/6, but the lack of detectable endogenous expression of Class Frizzled 
receptors, enabling to distinguish between WNT/FZD pairs activation the β-catenin pathway 
versus those that do not. Furthermore, characterization of the 32D parental line revealed that 
the cells contain little expression of WNTs, secreted frizzled-related proteins (sFRP) and 
dickkopf-related proteins (DKK). Additionally, the 32D cells do not express heparan sulfate 
proteoglycans (Richard et al., 1995), which is beneficial in our system because it excludes the 
confounding factor of WNT stickiness to the proteoglycans.  
In summary, this cellular system opens the avenue to study functionality of single FZD 
isoforms in a mammalian cell system, given the fact it shows functional β-catenin accumulation 
upon stimulation and holds biological relevant endogenous LRP5/6 and DVL expression.  
4.2 WNT-5A IN BRAIN (PATHO)PHYSIOLOGICAL PROCESSES 
4.2.1 WNT-5A induces a proinflammatory transformation in primary mouse microglia 
through ERK1/2 mediated signaling (Paper III) 
Brain inflammatory processes are a rewarding subject of study due to the fact that several CNS 
pathologies are accompanied by microglia activation, which can either be detrimental or 
beneficial (Querfurth & LaFerla, 2010). Previous work from our lab revealed a strong link 
between the activation of pro-inflammatory processes in microglia and WNT-3A. Furthermore, 
β-catenin levels are increased in microglia in post mortem brain from patients with AD as well 
as from the APdE9 (Swedish mutation of amyloid precursor protein and exon 9 deletion coding 
for presenilin 1) AD mouse model (Halleskog et al., 2011). These results indicate a role for the 
β-catenin pathway in CNS inflammatory processes. Other reports from our lab already showed 
activation of heterotrimeric G proteins, phosphorylated and shifted DVL (PS-DVL) and 
proliferation of the microglia-like cell line N13 (Kilander et al., 2011a, Kilander et al., 2011b). 
In paper III, we sought to investigate if the β-catenin-independent WNT-5A protein had 
physiological relevant effects on microglia and through which intracellular pathway this effect 
is exerted.   
To determine whether WNT-5A has physiological relevance in the brain we first 
investigated if and which cell type produces and secretes the protein in the CNS. Through 
immunohistochemistry, immunoblotting and qPCR experiments we pinpointed astrocytes as 
the main source of WNT-5A in the mouse adult brain, while microglia themselves show 
considerably less expression. WNT-5A signaling in microglia could thus be paracrine or to a 
lesser extend autocrine. In the search of dissecting the signaling cascade downstream of WNT-
5A, we employed several molecular pharmacological relevant assays. In agreement with 
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previous data, immunoblotting results revealed that WNT-5A does neither affect β-catenin 
stabilization nor phosphorylation of LRP6. However, it induced a dose- and time-dependent 
increase in the phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and 
DVL3. ERK1/2 belongs to the family of mitogen-activated protein kinases (MAPK), known 
for regulating various cellular processes such as proliferation, differentiation, apoptosis and 
embryogenesis. Other genes having distinct regulation and function within MAPKs family are 
for example the c-Jun N-terminal kinase (JNK(1-3)) and p38(alpha, beta, gamma and delta) 
families as well as the ERK5 branch (Raman et al., 2007). In this study we focused on ERK1/2 
activation, involved in various cellular processes such as cell motility and proliferation. 
Activation occurs for example after stimulation by growth factors and ligands for GPCRs or 
during cellular stress (Lewis et al., 1998, Chen et al., 2001). After applying the Gαi subunit 
inhibitor PTX, the P-ERK1/2 increase by WNT-5A was abolished. This implies that the WNT-
5A-induced MAPK signaling is activated by heterotrimeric G proteins, most likely transduced 
through FZDs. PS-DVL3 formation was not blocked by PTX, suggesting an alternative 
signaling branch being activated independent of G proteins. To support the finding of 
heterotrimeric G protein-activation, we performed GTPyS, cAMP and Ca2+ assays, processes 
typically involved in GPCR signaling. The results confirmed the functional activation of Gαi/o 
proteins by WNT-5A. By employing a set of inhibitors targeting different molecules important 
within MAPK signaling pathway, we were able to dissect the pathway activated downstream 
of WNT-5A. A schematic summary of those results are given in figure 7.  
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Figure 7: schematic overview of proposed signaling route in microglia downstream of WNT-5A. The 
pharmacological inhibitors employed are marked in gray. The question mark indicates unknown signaling route. 
Figure modified from Halleskog et al., 2012.  
We then returned to the question whether WNT-5A is physiologically relevant for microglia. 
As mentioned earlier, there is a strong link between inflammatory processes and WNT 
signaling in the brain. By stimulating microglia with WNT-5A, a strong pro-inflammatory 
(shown by increased expression of various pro-inflammatory genes), pro-invasive (figure 8B) 
and proliferative response was observed. It is known that MEK1 and -2 are upstream of 
ERK1/2, phosphorylating the tyrosine and threonine residues in the ERK1/2 activation loop 
(Roskoski, 2012). By employing the MEK inhibitor SL327, we revealed that activation of 
MEK1 and -2 are part of these processes, shown by a total abrogation of the invasion (figure 
8), proliferation and a partial blockade of the increased MMP 9 and 13 gene expression. Several 
other pro-inflammatory genes are not inhibited by SL327, suggesting that WNT-5A signaling 
is not solely transduced through the MAPK pathway. Possibly, the pathway branch involving 
the phosphorylation of DVL3 is part of this activation, since PS-DVL3 formation was not 
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affected by the Gαi protein inhibitor PTX. This could either occur through the activation of 
different FZDs – with their own distinct signaling route – or in parallel at the same receptor. 
 
 
Figure 8: Collagen invasion assay in primary microglia stimulated with WNT-5A. Visualized in (A): 
fluorescently labeled microglia are seeded on top of a 3D collagen IV layer and stimulated with either WNT-5A 
or Ctrl (PBS). After 24 hours, microglia are located within the collagen layer with confocal microscopy. The graph 
in (B) represents the percentage of invasion under different conditions. Figure modified from Halleskog et al., 
2012. 
4.2.2 WNT-5A is expressed by astrocytes in the rostral migratory stream and affects the 
neuronal precursor migration towards the olfactory bulb (Paper IV) 
Motivated by the results gathered from paper III, we continued our investigation on the location 
of WNT-5A expression in the brain and the role WNT-5A on physiological processes in the 
CNS. During brain developmental processes, WNT-5A is expressed by radial glia cells and 
functions to aid neuronal specification and positioning (Castelo-Branco et al., 2006). However, 
little is known about the role of WNT-5A in adulthood. Employing classical 
immunohistochemistry, we were able to map the distribution of WNT-5A in the mouse adult 
brain. During the initial characterization, we identified several regions of the brain clearly 
showing either subpopulations of neurons or non-defined subpopulation of astrocytes 
expressing high levels of WNT-5A. The WNT-5A-expressing neuronal population is 
predominantly present in the cortex. In the neurogenic regions including the hippocampus and 
subventricular zone (SVZ) and in the olfactory bulb (OB) and rostral migratory stream (RMS), 
especially the astrocytic population showed high expression of WNT-5A. This is in agreement 
with earlier reports, showing that astrocytic expression of WNT-5A has a role in the OB and 
controls neurite outgrowth during development and adulthood (Halleskog et al., 2012, Pino et 
al., 2011). In addition WNT-5A regulates the morphology and outgrowth of olfactory sensory 
neurons in vitro (Rodriguez-Gil & Greer, 2008). Careful investigation of the 
immunohistochemistry stainings of WNT-5A revealed, besides expression within the glial 
cells, a vesicular appearance of the protein distribution in certain areas of the brain. It is still a 
matter of debate how WNTs travel through the interstitial space but there are indications that 
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this transport is facilitated through exosome structures (Gross et al., 2012). Future research will 
shed light on the detailed structure of these vesicles, where they originate, and if they are 
dynamic or static.  
 
Figure 9: 3D rendering of a Z-stack imaged usinga superresolution microscopy from adult mouse brain stained 
with doublecortin (DCX; neuronal precursor), glial fibrillary acidic protein (GFAP; astrocyte) and WNT-5A. Note 
the GFAP/WNT-5A overlap and the close proximity of astrocyte and neuronal precursor. 
 
After showing the distribution of the WNT-5A in the adult mouse brain and revealing 
the SVZ-RMS-OB region as regions of interest, we were interested in the role of WNT-5A on 
neuronal processes ongoing in this area. In order to do so, we employed immunohistochemistry 
on EdU labeled WNT-5A+/- and +/+ mouse brain material. EdU incorporates into DNA of 
dividing cells, thereby labeling cells that undergo division e.g. neuronal precursor cells. The 
WNT-5A+ astrocytes do not co-localize with the EdU labeling, suggesting they do not present 
a stem cell population or are a source for neuronal precursors. However, WNT-5A+ astrocytes 
were distinctly marking the RMS and seemed to be in close proximity of the doublecortin+ 
(DCX) neuronal precursors. Employing super-resolution microscopy and 3D image analysis 
revealed that neuronal precursors in the RMS are indeed closely interacting with WNT-5A-
positive astrocytes (see figure 9), suggesting intricate communication between the cell types.  
Furthermore, in the heterozygous WNT-5A+/- mice an altered distribution pattern and 
increased number of EdU+ cells could be observed along the RMS. This suggests that the gross 
anatomy of the OB is altered compared to wild type mice, also illustrated by the difference in 
size of the OB glomeruli.  
In summary, based on this preliminary data, we hypothesize that a subpopulation of 
astrocytes present in the rostral migratory stream secrete WNT-5A as regulatory key to signal 
neuronal precursor migration. This process is of importance for the formation and maintenance 
of olfactory bulb integrity and function. Thus, astrocyte-secreted WNT-5A offers a cue for 
maintaining neuronal precursor migration along the RMS and thus a more general function 
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necessary for support of precursor migration resulting in the aid of stem-cell-dependent tissue 
maintenance and repair. The findings of study IV are schematically summarized in paper IV.  
 
 
Figure 10: Schematic presentation of paper IV. Astrocytes in the rostral migratory stream express high levels 
of WNT-5A in close proximity to migrating neuronal precursor cells on their way towards the olfactory bulb. 
Partial ablation of WNT-5A expression in adult WNT-5A+/- heterozygous mice results in widening of the astroglial 
tube in the RMS leading to a disturbed neuronal integration in the OB. NPC stands for neuronal precursor cell. 
 
4.2.3 Analysis of the presence and function of WNT-5A in human glioblastoma regarding 
inflammatory components (Paper V) 
Based on our previous work on WNT-5A signaling in relation to inflammatory pathway 
activation in microglia and a couple of reports linking WNT-5A signaling to glioma, we were 
inspired to investigate the involvement of WNT-5A in GBM. Yu et al. reported earlier the 
upregulation of WNT-5A in human glioma as well as in cultured glioma cell lines (Yu et al., 
2007). After initial immunohistochemistry experiments it became clear that indeed WNT-5A 
is highly expressed in GBMs on protein level. This finding was supported by a TCGA analysis 
in Oncomine, showing that the WNT-5A gene is 4.1 times upregulated in GBM samples 
compared to control brain tissue. The other members of the WNT family did not show a 
significant increased expression. The expression level of WNT-5A did not appear to have an 
effect on median survival of the patients. However, patient groups with higher expression of 
two members of the FZD family, that is FZD4 and FZD7, do show a difference in median 
survival of 2.1 and -4.2 months respectively (see figure 11), indicating potential pathway 
specificity in the response.  
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Figure 11: Kaplan-Meier curves between the patient groups expressing 25% low versus 25% high levels 
of WNT-5A, FZD4 and FZD7. The median survival in months between the low versus high expressing groups 
of WNT-5A, FZD4 and FZD7 are respectively: 14.7 - 15.1 (p = 0.423), 12.6 – 14.7 (p = 0.042) and 16.1 - 11.8 (p 
= <0.0001) months.  
 
In depth investigation of the group of genes higher expressed in the patient group with 25% 
highest level of WNT-5A (WNT-5Ahigh group) revealed an association to processes involved 
in immunology, such as the Gene Ontology terms immune response (GO:0006955) and antigen 
processing and presentation of peptide or polysaccharide antigen via MHC class II 
(GO:0002504). To perform this analysis we employed several open source bioinformatics 
platforms such as GSEA, DAVID and Cytoscape plus the additional plug-ins MiMI and 
MCode).  We were puzzled by the outcome, acknowledging the fact that GBMs generally 
create a local immunosuppressive microenvironment thereby avoiding potential anti-tumor 
immune response (Waziri, 2010). The activation of the antigen presentation pathway would 
suggest activated immune attack. Additional investigation led to the discovery that in the 
WNT-5Ahigh patient group known microglia markers (as described in kettenman et al. 2011) 
are enriched compared to the WNT-5Alow group. This indicates that increased WNT-5A levels 
in the GBM microenvironment correspond to higher presence of microglia within the tumor. 
Additionally, co-occurrence analysis revealed positive correlation between several microglia 
markers and the WNT-5A gene. The activated immunological processes in the WNT-5Ahigh 
group can possibly be explained by the higher incidence of microglia within the GBMs. We 
hypothesized that the increase in MHC class II components within the WNT-5Ahigh group can 
be due to the presence of microglia as well. Microglia are antigen presenting cells, hence 
capable of expressing MHC class II components on their cell surface. Indeed, 
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immunohistochemistry experiments done in tissue micro arrays of GBM samples, showed a 
strong correlation between the microglia marker IBA-1 (ionized calcium-binding adapter 
molecule 1) and HLA-DMA/DPB1. It remains questionable if the MHC class II on the surface 
of microglia is functional. Reports have shown that MHC Class II expression in TAM is either 
decreased, impaired or both. In agreement with that, we found that several essential 
components necessary for a fully functional antigen presentation response, such as CD40 and 
B7-1, are not enriched in the WNT-5A group and their overall expression is low. The findings 
of study V are summarized in a schematic overview as shown in the figure below. 
Collectively, even though one cannot draw direct conclusions on the effect of WNT-
5A on the progression of the tumor growth, the results of paper V pinpoints towards a novel 
role of WNT-5A on the presence of glioma-associated microglia infiltration. An investigation 
of a detailed phenotypical state of the microglia present in the WNT-5Ahigh GBM patient group 
would give us a better understanding if and how we can utilize this increased microglia invasion 
as a target for drug development.  
 
Figure 12: Schematic overview on the findings of paper V. The green circle represents the GBM and its 
microenvironment.  
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5 GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
In this thesis I aimed to create a better understanding of WNT/FZD signaling on 
different levels of medical research. With this intent, classic studies were combined to recent 
discoveries, pharmacological data compared to clinical studies, and physiological functions 
were related to pathophysiological alterations. The present chapter encloses scientific 
considerations regarding this aim. It is in no way intended to serve as a complete and round 
story, but rather a collection of thoughts that could help guiding future research.  
The ultimate goal of performing fundamental medical research is to develop treatment 
options against diseases. There is still, however, much to gain in bridging the gap between 
fundamental findings and the applied sciences. The field of translational sciences aims to apply 
results acquired in basic research into clinical use. This is, of course, a vital step ensuring basic 
research will at last improve public health. Currently, significant improvements have been 
made towards increased multidisciplinarity in medical sciences. They include genomic 
screenings of patient groups, the use of bioinformatical tools to comprehend the often vast 
amount of data, and the intent to develop personalized medicine in order to employ this 
knowledge with higher effectivity. To achieve these goals, future challenges include the 
establishment of better communication between scientist from different research areas, as well 
as clinicians, patients and the population as a whole. In my opinion, it would be immensely 
beneficial to integrate opinions and knowledge from various disciplines to strengthen medical 
research. 
There are interesting questions raised by the research presented in this thesis that 
deserve additional attention. The first is, naturally, the potential use of WNT/FZD signaling as 
target for therapy. To define the druggability of the WNT/FZD signaling pathway, numerous 
aspects should be taken into consideration. From a broader perspective, one should first 
determine the specific link of the pathway to different diseases. Are we dealing with mutations, 
alteration of gene expression of specific molecules, or rather disturbance of parts or the whole 
regulatory pathway affecting the disease progression? For instance, the supposed role that 
FZD4, FZD6 and APC play in, respectively, familial exudative vitreoretinopathy (FEVR) 
(Wang et al., 2012), nail dysplasia (Frojmark et al., 2011) and colorectal cancer (Clevers, 
2004), are caused by specific mutations within the protein codes in the DNA. The follow up 
question that logically can be asked is what the effect of this mutation is on the functionality of 
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the protein. In the case of FZD6 in nail dysplasia, it is known that the receptor is still produced, 
but is not translocated efficiently to the membrane due to a missense mutation. This results in 
non-functional WNT/FZD signaling. The development of drugs for this disease would require 
a different approach than, e.g., colorectal cancer, where a premature stop codon leads to a 
complete dysfunctional formation of the APC protein.  
The contribution of WNT-5A in the glioma disease progression is not entirely clear. In 
paper V, we do conclude that an increase in WNT-5A gene expression results in higher protein 
levels in the tumor microenvironment. Furthermore, in patients whose gliomas express high 
levels of WNT-5A, a larger number of microglia could be observed. However, this positive 
association does not seem to affect survival, as indicated by the comparison of the survival 
curves of low- versus high-expressing patient groups. Thus, the link between WNT-5A and the 
disease can be strong, but the question remains whether WNT-5A could be used as a 
therapeutic target for drugs. Likewise, will it be beneficial for the patient? Additionally, a body 
of literature, as well as the findings reported in paper III and IV, provide evidence that WNT-
5A does have a crucial function in brain development and maintenance processes. If one would 
simply antagonize WNT-5A, other essential processes could be inhibited, possibly leading to 
undesirable side effects. The presence of microglia surrounding the tumor is often associated 
with poor disease prognostic for several reasons (Yang et al., 2010). It would be interesting to 
explore the possibility to pharmacologically activate the immune-competent cells to trigger 
immune attack against the cancer cells, thus halting the disease progression. Recent 
developments in cancer immunotherapy indicate that body’s own immune cells can be used to 
eliminate the tumor (Hodi et al., 2010). This can be done through different approaches, for 
instance by a non-specific boost of the immune system or the development of a cancer vaccine. 
The fact that WNT-5A and MHC Class II components show high correlation is promising, 
even though the MHC Class II does not seem to be functional. Future studies could investigate 
the reason why the antigen presentation is not functional within the tumor, and investigate ways 
to stimulate the immune cells in a way it can efficiently function as proper defense system 
against cancer. An example of a drug that is currently commercially available and uses a similar 
approach is the Ipilimumab (Yervoy®), a monoclonal antibody that blocks CTLA-4 receptors. 
This blocking “lifts” the immune checkpoint that usually prevents T-cells to attack cells 
belonging to its own body (Shin & Ribas, 2015). This same checkpoint prevents immune cell 
to attack the cancer cells. Therefore, WNT-5A could be considered in glioma therapy, knowing 
it (i) induces proinvasive behavior in microglia (paper III) (ii) initiates a proinflammatory 
response and is positively correlated with parts of the MHC Class II component genes in GBM 
(paper III and IV), and could therefore help inducing an anti-tumor immune attack. 
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Recombinant WNT-5A or small molecules mimicking WNT-5A function may serve as an 
adjuvant therapy in combination with other drugs boosting the general immune attack or lifting 
the immune check points in microglia. Although tempting to speculate on, the serious side 
effects that this type of treatments might induce (e.g. life threatening whole body immune 
attack) should not be neglected. 
Downstream signaling components or parts of the pathways can also serve as possible 
candidates for drug therapy. In paper I we identify the WNT-5A-induced activation of 
heterotrimeric G proteins and in paper III the importance of ERK1/2 phosphorylation for the 
WNT-5A-induced expression of MMP 9 and 13, invasion and proliferation in microglia. The 
disadvantage of targeting for example heterotrimeric G proteins or ERK1/2 is that these 
components are essential in many more cellular processes of the body.  Inhibition or blocking 
will therefore be physiologically highly unspecific and likely to cause multiple side effects. 
However, stipulating the activation of heterotrimeric G proteins causing the disease, 
development of specific cell permeable nanobodies targeting the potential G protein-binding 
site of the FZDs would be an interesting approach. These nanobodies can serve as activators, 
inhibitors or biased signaling molecules for G proteins on the intracellular domains of FZDs. 
The development of such drugs requires excellent screening methods for G protein activation 
transduced by FZDs, as proposed by Koval & Katanaev (Koval & Katanaev, 2012).   
Important to note is that, before even considering applying drugs to target FZDs intra- 
or extracellular, the receptor expression repertoire present in the area of interest and the 
interplay between the various activated downstream signaling components should be taken into 
account. This because, by simply blocking one receptor, an alternative signaling pathway may 
be over-activated resulting in either beneficial or detrimental effects. For instance, antagonizing 
solely FZD7 due its role in different cancer types can lead to augmented receptor occupancy of 
for example FZD2 which in turn might lead to for example increased Ca
2+ signaling. The 
consequences of the overrepresentation of this pathway are difficult to oversee. Furthermore, 
by recognizing that certain WNT/FZD pairs exhibit functional selectivity (paper II), one should 
keep in mind that a specific isoform of WNT does not solely activate one specific pathway but 
that it depends on the receptors present. The same accounts for the specific FZDs, where the 
presence of WNT repertoire defines the activation of downstream signaling components. 
Although this knowledge creates a more complex general picture, it may prove to be useful as 
now the characteristics of the functional selectivity can be employed. In the event that a certain 
disease is solely induced by the β-catenin-dependent signaling, the possibility to skew pathway 
activation towards β-catenin-independent signaling can be achieved by either blocking specific 
FZDs, WNTs or co-receptors.  
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Another important factor to consider regarding the use WNT/FZD pathway in future therapy 
is to question if and how suitable targets can be reached. For example, to augment the existing 
pathway, the use of recombinant WNT as therapeutic proteins could be difficult to apply 
systemically. Given the fact rWNTs will only be able to bind FZDs and subsequently exert 
their function when the protein structure is unaffected, a tablet or capsule as administration 
route is out of the question. Furthermore, systemic administration through for example an 
intravenous injection can be challenging due to the lipid modified structure of WNTs, affecting 
the distribution of the drug throughout the body and making the pharmacokinetic properties 
hard to predict. If however a high local concentration at a specific target site would be desirable, 
injection with rWNTs might be realistic and effective. As an alternative to recombinant whole 
proteins, small molecules mimicking or antagonizing WNTs at the site of the receptor can be 
used. The distribution of small molecules or peptides throughout the body is certainly more 
feasible. Furthermore, reaching the target site can be improved by applying biochemical design 
and modifications to the molecules. There are several potential avenues to pursue regarding the 
design of pharmacological agents in WNT/FZD pathway. With the current finding of the 
orthosteric binding site of FZD8 and the acknowledgment that there is a potential bias in the 
signaling pathway, the possibilities of the development of various pharmacological agents such 
as agonists, inverse agonists, allosteric modulators, biased ligand or antagonist come within 
reach. The development of good screening methods however, is critical for success.  
Additionally, in paper IV we identify astrocytes as one of the main sources of WNT-
5A production in the CNS and discovered it serves as a migratory stimulant in neuronal 
precursor migration from the SVZ to the OB. This feature may be of use in therapies where 
integration of new neurons is required e.g. brain damage, stroke or Parkinson’s disease. 
Although highly speculative, stimulating astrocytes to produce and secrete WNT-5A resulting 
in an induction of neuronal precursor migration to the injured site could therefore be beneficial.   
In summary, the results encompassed in this thesis contribute to the understanding of 
WNT/FZD signaling in general. It comprises several levels of investigation, ranging from basic 
pharmacological properties of ligand binding to physiological and pathophysiological 
relevance in the CNS. The aim of this work is to contribute on the foundations of future 
therapeutic approaches based on either altering dysfunctional components or by employing 
physiological functional components of the pathway. 
  
  41 
6 CONCLUSIONS 
Paper I 
1. WNT-5A can induce the exchange of GDP for GTP at heterotrimeric G proteins in the 
microglia-like cell line N13.  
2. The exchange is PTX sensitive, pinpointing Gαi/o family proteins as the responsible subunit 
for the G protein activitation 
3. Assesment of  the FZD and G protein repetoire in N13 cells indicates FZD5 and the Gαi2/3-
subunit as signaling components most likely to transduce the WNT-5A-induced activation 
of heterotrimeric G proteins. 
Paper II 
1. The myeloid progenitor cell line 32D does not express endogenous FZDs. It is however 
possible to overexpress FZD in these cells allowing us to investigate individual functional 
WNT/FZD pairs and downstream signaling specificity.   
2. WNT-3A, -4, -5A are functional binding partners to FZD2,4,5 with different affinities to the 
CRD domains of the FZDs and have a putative functional selectivity for individual 
downstream signaling pathways.  
Paper III 
1. Recombinant WNT-5A stimulation induces proliferation and causes a proinflammatory 
and pro-invasive response in mouse primary microglia in vitro.  
2. WNT-5A causes phosphorylation of  ERK1/2, activation of the subunits Gαi/o and β/γ and 
phospholipase C, PKC and MEK1/2 in primary microglia. Additionally, it induces 
invasion, proliferation and increase in Ca2+ signaling. 
3. Inhibition of the MEK1/2 pathway by SL327 blocks invasion, proliferation and the gene 
upregulation of metalloproteases 9/13, indicating that WNT-induced G protein signaling is 
biologically relevant.  
Paper IV 
1. WNT-5A is highly expressed by astrocytes in the mouse rostral migratory stream and 
olfactory bulb 
2. Partial ablation of WNT-5A causes (i) an increase in the proliferation of neuronal 
precursors and (ii) an altered cellular organization of the RMS/OB arguing for a crucial 
role of astrocytic WNT-5A to guide neuronal progenitor cells along the RMS.  
Paper V 
1. WNT-5A is upregulated in human glioma tissue shown by immunhistochemistry.  
2. High WNT-5A expression is associated with pro-inflammatory effects in the glioma 
microenvironment and with an increased microglia infiltration.  
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